

Table S1**Baseline characteristics of patients on the waiting list, n=256**

Age, median (range)	54 (22 - 77)
Female gender, n (%)	83 (32.4)
≥ 2 nd TX, n (%)	53 (20.7)
Standard ETKAS patients, n (%)	202 (78.9)
ESP, n (%)	33 (12.9)
AM-Program, n (%)	7 (2.7)
CDC-PRA <5, 5-84, >85, (%)	
Current	88.3 / 10.9 / 0.8
Highest	67.2 / 26.6 / 6.3
Patients with HLA-Abs by Luminex, n (%)	134 (52.3)
HLA-Abs per patient, median (IQR)	23 (8-18)
Number of patients with HLA-Abs against class I+II, n (%)	66 (49.3)

ETKAS, Eurotransplant kidney allocation system; ESP, Eurotransplant senior program; AM, acceptable mismatch; MFI, mean fluorescence intensity

Table S2**Tacrolimus trough levels posttransplantation**

Patient group	Tac trough level at 1 year [μg/l] mean (95% CI)	Tac trough level at 3 years [μg/l] mean (95% CI)
DGI UAM-	7.1 (6.4 - 7.7)	5.5 (4.9 – 6.1)
DGI UAM+ AMR-	7.2 (6.5 - 8.0)	5.1 (4.3 – 5.9)
ME UAM-	7.0 (6.5 - 7.5)	5.7 (5.1 – 6.3)
ME UAM+ AMR-	7.4 (6.4 - 8.5)	4.7 (4.1 – 5.2)
AMR+	7.1 (5.8 - 8.4)	5.3 (4.4 – 6.2)